179 related articles for article (PubMed ID: 19690349)
1. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY; Rasmussen LH; Olsson SB; Jensen EC; Persson AL; Eriksson U; Wåhlander KF;
Eur Heart J; 2009 Dec; 30(23):2897-907. PubMed ID: 19690349
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Lip GY; Rasmussen LH; Olsson SB; Jensen E; Hamrén B; Eriksson UG; Wåhlander K
Br J Clin Pharmacol; 2015 Dec; 80(6):1362-73. PubMed ID: 26174611
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Olsson SB; Rasmussen LH; Tveit A; Jensen E; Wessman P; Panfilov S; Wåhlander K
Thromb Haemost; 2010 Mar; 103(3):604-12. PubMed ID: 20076850
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Salazar CA; del Aguila D; Cordova EG
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
[TBL] [Abstract][Full Text] [Related]
5. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Lip GY; Rasmussen LH; Olsson SB; Zetterstrand S; Stahre C; Bylock A; Aunes-Jansson M; Eriksson U; Wåhlander K;
Thromb Res; 2011 Feb; 127(2):91-9. PubMed ID: 21172721
[TBL] [Abstract][Full Text] [Related]
6. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM; Berge E
Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
Halperin JL
J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
[TBL] [Abstract][Full Text] [Related]
10. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
[TBL] [Abstract][Full Text] [Related]
12. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.
Christersson C; Wallentin L; Andersson U; Alexander JH; Ansell J; De Caterina R; Gersh BJ; Granger CB; Hanna M; Horowitz JD; Huber K; Husted S; Hylek EM; Lopes RD; Siegbahn A
J Thromb Haemost; 2014 Sep; 12(9):1401-12. PubMed ID: 24942912
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW
J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
[TBL] [Abstract][Full Text] [Related]
16. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
17. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
18. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
